Key result
Allisartan isoproxil lowered systolic blood pressure similarly to nifedipine (decrease of 19.88 mm Hg vs 17.96 mm Hg), while significantly improving left ventricular remodeling and renal injury.
Why the study?
Angiotensin II type 1 receptor antagonists lower blood pressure and protect target organs, but these effects had not been demonstrated for allisartan isoproxil in patients with mild to moderate essential hypertension.
Does allisartan isoproxil reduce blood pressure and target organ injury compared to nifedipine in patients with mild to moderate essential hypertension?
RCT (n=80)
Double-blind
Random number method
No
Does allisartan isoproxil reduce blood pressure and target organ injury compared to nifedipine in patients with mild to moderate essential hypertension?
Absolute Event Rate: -19.88% vs -17.96%
p-value: p=>0.05
Allisartan isoproxil is as effective as nifedipine in lowering blood pressure but provides additional benefits in improving left ventricular remodeling, renal injury, and endothelial function in patients with mild to moderate essential hypertension.
Allisartan isoproxil matched nifedipine for BP reduction in mild hypertension; leaves open confirmation of target organ benefits in larger trials.
Evidence has shown that angiotensin II type 1 receptor antagonists have lower blood pressure and have target organ protective effects, but this is not the case for the drug allisartan isoproxil. The aim of this study was to evaluate the effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension.In total, 80 essential hypertensive participants were randomly divided into an allisartan group and a nifedipine group (n = 40 per group), and their blood pressure was measured once per month for 6 months. A 2-dimensional echocardiogram was performed at baseline and at the end of the study. The serum levels of renal injury indexes, endothelial function markers, inflammatory factors, blood biochemical assays and urinary measurements were determined at baseline and at 6 months.At the end of the study, both systolic and diastolic blood pressure were significantly decreased in the allisartan group compared with baseline and showed the same antihypertensive effect as the nifedipine group. Meanwhile, the left ventricular remodeling, 24-hours levels of urinary microalbumin, endothelial dysfunction, and arterial stiffness were all significantly improved compared with that of the baseline and the nifedipine group (all P < .05).The present study showed that allisartan isoproxil had favorable blood pressure lowering and heart, renal, and endothelial protective effects in patients with mild to moderate essential hypertension.
No takes yet. Share an insight, caveat, or question.
Jian-qi et al. (2019) conducted an RCT in Mild to moderate essential hypertension (n=80). Allisartan isoproxil vs. Nifedipine GITS 30 mg per day was evaluated on Change in systolic blood pressure (SBP) (p=>0.05). Allisartan isoproxil lowered systolic blood pressure similarly to nifedipine (decrease of 19.88 mm Hg vs 17.96 mm Hg), while significantly improving left ventricular remodeling and renal injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: